– USA, CA – Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary gene editing toolbox, announced the appointment of Eric Bjerkholt to its Board of Directors effective January 27, 2025.
“We are excited to welcome Eric to our Board of Directors. His tremendous track record in the pharmaceutical industry as well as his experience in business development and capital formation will be an invaluable asset to Metagenomi as we continue to advance potentially curative treatment options for patients suffering from devastating disease,” said CEO and Founder , Dr. Brian Thomas.
Eric Bjerkholt will also join the Audit and Compensation Committees
About Eric Bjerkholt
Eric Bjerkholt brings extensive business leadership experience across a broad range of roles and is CFO of Mirum Pharmaceuticals, Inc. He joined Mirum from Chinook Therapeutics, Inc., where he served as CFO overseeing financial reporting, planning and budgeting, internal controls, investor relations, facilities, and information technology functions. Chinook was acquired by Novartis AG. Before Chinook, Eric Bjerkholt was CFO of Aimmune Therapeutics, which was acquired by Nestle Health Science. Previously, he worked at Sunesis Pharmaceuticals, Inc., serving in various roles including EVP of Corporate Development and Finance, Corporate Secretary, and Chief Compliance Officer.
“I am thrilled to join Metagenomi at this important time of innovation and clinical validation in the broader gene editing space,” said Eric Bjerkholt. “I am excited to collaborate with the Board and the management team, which brings together some of the brightest innovators and industry veterans, to accelerate our development of precision genetic medicines.”
Eric Bjerkholt has also held senior executive finance roles at IntraBiotics Pharmaceuticals, Inc., LifeSpring Nutrition, Inc., and Age Wave, LLC. He spent seven years in healthcare investment banking at J.P. Morgan & Company, Inc.
Eric Bjerkholt holds an MBA from Harvard Business School and a Cand.oecon. From the University of Oslo in Norway.
About Metagenomi
Metagenomi is a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived toolbox. Metagenomi is harnessing the power of metagenomics, the study of genetic material recovered from the natural environment, to unlock four billion years of microbial evolution to discover and develop a suite of novel editing tools capable of correcting any type of genetic mutation found anywhere in the genome. Its comprehensive genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems (including prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases (CAST)). Metagenomi believes its diverse and modular toolbox positions the company to access the entire genome and select the optimal tool to unlock the full potential of genome editing for patients.
For more: https://metagenomi.co/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.